🇺🇸 FDA
Pipeline program

ALN-XDH

ALN-XDH-001

Phase 2 small_molecule terminated

Quick answer

ALN-XDH for Gout is a Phase 2 program (small_molecule) at ALNYLAM PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
ALNYLAM PHARMACEUTICALS, INC.
Indication
Gout
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials